Search clinical trials for: rifaximin

Total 189 results

Cedars-Sinai Medical Center
Bausch Health Ireland Limited

Completed

Efficacy and Safety of Rifaximin With NAC in IBS-D

Irritable Bowel Syndrome With Diarrhea

United States
Henry M. Jackson Foundation for the Advancement...
Naval Medical Research Center; Ministry of Defence, United Kingdom

Completed

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

Reactive Arthritis | Travelers' Diarrhea | Functional Bowel Disorders

United States, Kenya
Changi General Hospital

Terminated

Primary Prophylaxis for Spontaneous Bacterial Peritonitis (SIBOC)

Decompensated Cirrhosis | Small Bowel Bacterial Overgrowth Syndrome

Singapore
Samar Atef Sebaweh Mohammed

Completed

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

Ascites Infection

Egypt
AB Biotics, SA

Terminated

Effect of a Probiotic Formula on Reducing SIBO in IBS Patients

Irritable Bowel Syndrome | Small Intestinal Bacterial Overgrowth

Spain
Cedars-Sinai Medical Center
Bausch Health Americas, Inc.

Terminated

Rifaximin on Visceral Hypersensitivity

Irritable Bowel Syndrome | Visceral Hypersensitivity

United States
Columbia University
Bausch Health Americas, Inc.

Completed

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Celiac Disease

United States
National University Hospital, Singapore
National University, Singapore

Completed

Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea

Singapore
Coordinación de Investigación en Salud, Mexico

Terminated

Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial

Liver Cirrhosis | Small Intestinal Bacterial Overgrowth

Mexico
Weill Medical College of Cornell University

Withdrawn

Rifaximin Versus Lactulose in Renal Failure

Liver Cirrhosis | Renal Failure

United States
Duke University
Bausch Health Americas, Inc.

Completed

Trial of Rifaximin in Probable Alzheimer's Disease

Alzheimer's Disease

United States
Scott Lee
Bausch Health Americas, Inc.

Completed

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Crohn's Disease

United States
Jason Stubbs, MD

Completed

Rifaximin Therapy in Chronic Kidney Disease

Chronic Kidney Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
National Institute of Allergy and Infectious Diseases...

Completed

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

HIV Infections | Lymphoma, Non-Hodgkin

United States
RWTH Aachen University

Terminated

Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection (ARROW)

Malignant Liver Disease | Major Liver Resection

Germany
Alfasigma S.p.A.

Terminated

Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. (ROAD)

Diverticulitis

France, Germany, Italy, Netherlands, Spain, United Kingdom
University of Nottingham
National Institute for Health Research, United Kingdom

Completed

Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea (RAPID)

Clostridium Difficile Infection

United Kingdom
Emory University

Completed

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

Microbial Colonization

United States
Seattle Children's Hospital

Terminated

Fecal Microbial Transplant in Pediatric Crohn's Disease (FMTCD)

Crohn's Disease

United States
Alfasigma S.p.A.
Cromsource

Terminated

A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention (STOP-PER)

Crohn Disease

Italy
Mallinckrodt

Completed

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

Hepatic Cirrhosis | Hepatic Encephalopathy (HE)

United States, Puerto Rico
Shanghai Changzheng Hospital

Completed

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

Covert Hepatic Encephalopathy

China
Yokohama City University
ASKA Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial

Chronic Intestinal Pseudo-obstruction

Japan
Bausch Health Americas, Inc.

Completed

Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers

Healthy Volunteers

New Zealand
David E. Kaplan, MD MSc
Bausch Health Americas, Inc.

Terminated

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Liver Cirrhosis | Chronic Hepatitis C

United States
Bogomolets National Medical University

Completed

Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy

Liver Cirrhosis | Hepatic Encephalopathy | End Stage Liver DIsease
Ospedali Riuniti di Foggia

Active, not recruiting

Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis

Spontaneous Bacterial Peritonitis

Italy
National Hepatology & Tropical Medicine Research...

Completed

Microbial Resistance of Rifaximin in Hepatic Encephalopathy

Hepatic Encephalopathy
Torre Médica Santé

Completed

Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease

Parkinson's Disease Aggravated

Mexico
Bayhealth Medical Center

Unknown

Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet

Weight Loss

United States
Hunter Holmes Mcguire Veteran Affairs Medical Center
Bausch Health Americas, Inc.

Completed

Rifaximin in Minimal Hepatic Encephalopathy

Hepatic Encephalopathy

United States
Imperial College London
National Health Service, United Kingdom

Terminated

Rifaximin in Fatty Liver Disease (RiFL)

NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United Kingdom
Second Affiliated Hospital, School of Medicine,...
Peking Union Medical College Hospital; RenJi Hospital; Sir Run Run Shaw Hospital and other collaborators

Unknown

Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D

Gut Microbiota | IBS - Irritable Bowel Syndrome

China
University Hospital, Toulouse

Completed

Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS (PRPET)

Cirrhosis

France
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

Rifaximin for Chronic Immune Activation in People With HIV

HIV

United States
Bausch Health Americas, Inc.

Completed

Rifaximin for Prevention of Travellers' Diarrhea

Diarrhea

Mexico
Actavis Inc.

Completed

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

Diarrhea

United States
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 2)

Non-Constipation Irritable Bowel Syndrome

United States
Bausch Health Americas, Inc.

Completed

Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers

Pharmacokinetic
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 1)

Non-Constipation Irritable Bowel Syndrome

United States, Canada
Bausch Health Americas, Inc.

Completed

Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

Diarrhea

United States
Bausch Health Americas, Inc.

Completed

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Washington University School of Medicine
Baylor College of Medicine; Kamuzu University of Health Sciences; United States...

Completed

Trial of Rifaximin in the Treatment of Tropical Enteropathy

Tropical Enteropathy

Malawi
Northwestern University

Withdrawn

Autologous Transplant Targeted Against Crohn's (ATTAC)

Crohn's Disease

United States
Institute of Liver and Biliary Sciences, India

Withdrawn

High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.

Refractory Hepatic Encephalopathy

India
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
Bausch Health Americas, Inc.

Completed

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Diarrhea | Clostridium Infections

United States
Bausch Health Americas, Inc.

Completed

A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

Hepatic Encephalopathy
University of Miami
Bausch Health Americas, Inc.

Terminated

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

Hepatic Encephalopathy

United States

Search clinical trials for: rifaximin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations